DexCom, Inc. $DXCM Shares Newly Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 278,822 shares of the medical device company’s stock, valued at approximately $24,060,000.

Several other institutional investors and hedge funds have also recently modified their holdings of DXCM. Latitude Advisors LLC purchased a new stake in shares of DexCom in the third quarter worth approximately $32,000. Hilton Head Capital Partners LLC boosted its holdings in DexCom by 242.3% during the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after acquiring an additional 269 shares during the last quarter. Ascentis Independent Advisors bought a new position in shares of DexCom during the first quarter valued at about $25,000. Elevation Wealth Partners LLC lifted its position in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 152 shares in the last quarter. Finally, GK Wealth Management LLC purchased a new position in DexCom during the third quarter worth about $35,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $84.76 on Tuesday. The company has a market capitalization of $31.99 billion, a P/E ratio of 33.24, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. The company’s 50-day moving average is $85.67 and its 200 day moving average is $74.73. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $92.59.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter last year, the company posted $0.61 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. On average, equities research analysts forecast that DexCom, Inc. will post 2.67 earnings per share for the current year.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Canaccord Genuity Group raised its price target to $97 from $90 and upgraded DexCom to “buy,” implying approximately 14.4% upside from the referenced price. Canaccord Genuity Group recommendations
• Positive Sentiment: UBS raised its price target to $107 from $102 and maintained or assigned a “buy” view, representing approximately 26.2% potential upside. The higher target reflects confidence in DexCom’s growth prospects. UBS Group recommendations
• Positive Sentiment: DexCom exceeded third-quarter expectations, reporting adjusted earnings of $0.73 per share versus the $0.68 consensus estimate and revenue of approximately $1.34 billion versus $1.33 billion expected. Revenue grew 11.1% year over year, reinforcing the company’s operating momentum. DexCom third-quarter results presentation
• Positive Sentiment: Recent coverage points to improving patient access, clinical momentum, and new product launches as factors supporting DexCom’s longer-term growth trajectory. DexCom improving patient access article
• Neutral Sentiment: Additional reports cited analyst price targets ranging from $85 to $120, indicating a generally constructive but varied view of DexCom’s valuation and upside potential. DexCom price target report

Insider Activity at DexCom

In other news, EVP Jereme M. Sylvain sold 3,638 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the completion of the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total transaction of $145,316.00. Following the transaction, the executive vice president directly owned 98,185 shares of the company’s stock, valued at $8,392,853.80. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,822 shares of company stock valued at $1,920,193 in the last three months. Insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on DXCM shares. Mizuho set a $100.00 target price on shares of DexCom in a research report on Tuesday, October 13th. Piper Sandler restated an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Weiss Ratings raised DexCom from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, October 6th. UBS Group increased their price target on DexCom from $102.00 to $107.00 and gave the company a “buy” rating in a research report on Friday. Finally, Robert W. Baird set a $105.00 price target on DexCom and gave the stock an “outperform” rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, DexCom has a consensus rating of “Buy” and a consensus target price of $95.50.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.